KAYNAKLAR
1. Ueshima H, Iida M, Shimamoto T, Konishi M, Tsujioka K, Tanigaki M, et al. Multivariate analysis of risk factors for stroke. Eight-year follow-up study of farming villages in Akita, Japan. Prev Med. 1980;9:722–40.
2. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904–10.
3. Cummings P, Psaty BM. The association between cholesterol
and death from injury. Ann Intern Med. 1994;120:848–55.
4. Lester D. Serum cholesterol levels and suicide: a meta-analysis. Suicide Life Threat Behav. 2002;32:333–46.
5. Epstein FH. Low serum cholesterol, cancer and other oncardiovascular disorders. Atherosclerosis. 1992;94:1–12.
6. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306:1367–73.
7.Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9.
9. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007;50:409–11.
10.
http://www.jstage.jst.go.jp/article/jea/21/1/67/_pdf Genişletmek için tıkla...